Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 6/2009

01-11-2009

Autoimmunity, Infectious Immunity, and Atherosclerosis

Authors: Eiji Matsuura, Kazuko Kobayashi, Yukana Matsunami, Lianhua Shen, Nanhu Quan, Marina Makarova, Sergey V. Suchkov, Kiyoshi Ayada, Keiji Oguma, Luis R. Lopez

Published in: Journal of Clinical Immunology | Issue 6/2009

Login to get access

Abstract

Introduction

Vascular inflammation is common in certain systemic autoimmune diseases and contributes to the oxidation of low-density lipoprotein (oxLDL) and oxLDL/β2-glycoprotein I (β2GPI) complex formation. These complexes have been implicated as proatherogenic autoantigens that participate in the development of atherosclerotic disease.

Discussion

We have demonstrated that the in vitro macrophage uptake of oxLDL/β2GPI complexes increases in the presence of IgG anti-β2GPI antibodies and that IgG immune complexes containing oxLDL/β2GPI upregulate the expression of both scavenger and Fcγ receptors to activate β2GPI-specific T cells. Some persistent infections may cause immune responses that promote atherogenesis. Cellular immunity (Th1) against Helicobacter pylori (H. pylori) derived heat shock protein 60 (Hp-HSP60) cross-reacts with endogenous HSP60 to cause cardiovascular disease likely by molecular mimicry.

Conclusion

Infectious cellular response may be proatherogenic, while the humoral response (antibody production) may be protective. We review the recent progress in our understanding of autoimmunity and infectious immunity that promote atherosclerosis.
Literature
1.
Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112:3337–47.CrossRefPubMed
2.
Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol. 1986;13:486–9.PubMed
3.
Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Kobayashi S, et al. Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum. 1996;39:1466–74.CrossRefPubMed
4.
Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA. Anti-β2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol. 2004;121:142–9.CrossRefPubMed
5.
George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, et al. Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation. 1999;99:2227–30.PubMed
6.
Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, et al. Evidence for presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086–95.CrossRefPubMed
7.
8.
9.
Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983–6.CrossRefPubMed
10.
Altannavch T, Roubalova K, Broz J, Hruba D, Andel M. Serological markers of Chlamydia pneumoniae, cytomegalovirus and Helicobacter pylori infection in diabetic and non-diabetic patients with unstable angina pectoris. Cent Eur J Public Health. 2003;11:102–6.PubMed
11.
Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation. 1999;100:e20–28.PubMed
12.
Erkkila L, Laitinen K, Haasio K, Tiirola T, Jauhiainen M, Lehr HA, et al. Heat shock protein 60 autoimmunity and early lipid lesions in cholesterol-fed C57BL/6JBom mice during Chlamydia pneumoniae infection. Atherosclerosis. 2004;177:321–8.CrossRefPubMed
13.
Choi JI, Chung SW, Kang HS, Rhim BY, Kim SJ, Kim SJ. Establishment of Porphyromonas gingivalis heat-shock-protein-specific T-cell lines from atherosclerosis patients. J Dent Res. 2002;81:344–8.CrossRefPubMed
14.
Bason C, Corrocher R, Lunardi C, Puccetti P, Olivieri O, Girelli D, et al. Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet. 2003;362:1971–7.CrossRefPubMed
15.
Harats D, Yacov N, Gilburd B, Shoenfeld Y, George J. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol. 2002;40:1333–8.CrossRefPubMed
16.
Ayada K, Yokota K, Kobayashi K, Shoenfeld Y, Matsuura E, Oguma K. Chronic infections and atherosclerosis. Ann N Y Acad Sci. 2007;1108:594–602.CrossRefPubMed
17.
Ayada K, Yokota K, Hirai K, Fujimoto K, Kobayashi K, Ogawa H, et al. Regulation of cellular immunity prevents Helicobacter pylori-induced atherosclerosis. Lupus 2009; in press
18.
Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963–6.CrossRefPubMed
19.
Shoenfeld Y, Wu R, Dearing LD, Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation. 2004;110:2552–8.CrossRefPubMed
20.
Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990;336:177–8.CrossRefPubMed
21.
Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med. 1994;179:457–62.CrossRefPubMed
22.
Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol. 1997;107:569–73.CrossRefPubMed
23.
Kobayashi K, Matsuura E, Liu Q, Furukawa J, Kaihara K, Inagaki J, et al. A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res. 2001;42:697–709.PubMed
24.
Matsuura E, Kobayashi K, Tabuchi M, Lopez LR. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res. 2006;45:466–86.CrossRefPubMed
25.
Kobayashi K, Kishi M, Atsumi T, Bertolaccini ML, Makino H, Sakairi N, et al. Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res. 2003;44:716–26.CrossRefPubMed
26.
Kobayashi K, Tada K, Itabe H, Ueno T, Liu P-H, Tsutsumi A, et al. Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages. Lupus. 2007;16:929–38.CrossRefPubMed
27.
Kajiwara T, Yasuda T, Matsuura E. Intracellular trafficking of β2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome. J Autoimmun. 2007;29:164–73.CrossRefPubMed
28.
Kuwana M, Matsuura E, Kobayashi K, Okazaki Y, Kaburaki J, Ikeda Y, et al. Binding of β2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood. 2005;105:1552–7.CrossRefPubMed
29.
Yamaguchi Y, Seta N, Kaburaki J, Kobayashi K, Matsuura E, Kuwana M. Excessive exposure to anionic surfaces maintains autoantibody response to β2-glycoprotein I in patients with antiphospholipid syndrome. Blood. 2007;110:4312–8.CrossRefPubMed
30.
Tabuchi M, Inoue K, Usui-Kataoka H, Kobayashi K, Teramoto M, Takasugi K, et al. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res. 2007;48:768–81.CrossRefPubMed
31.
Dunoyer-Geindre S, Kruithof EK, Galve-de Rochemonteix B, Rosnoblet C, Gruenberg J, Reber G, et al. Localization of β2-glycoprotein 1 in late endosomes of human endothelial cells. Thromb Haemost. 2001;85:903–7.PubMed
32.
Galve-de Rochemonteix B, Kobayashi T, Rosnoblet C, Lindsay M, Parton RG, Reber G, et al. Interaction of anti-phospholipid antibodies with late endosomes of human endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:563–74.PubMed
33.
Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–5.CrossRefPubMed
34.
Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 2005;100:1037–42.CrossRefPubMed
35.
Kawahara Y, Yokota K, Mizuno M, Yunoki N, Uesu T, Okada H, et al. Antibodies to human gastric epithelial cells and heat shock protein 60 in Helicobacter pylori positive mucosa associated lymphoid tissue lymphoma. Gut. 1999;45:20–3.PubMedCrossRef
36.
Inaba T, Mizuno M, Take S, Suwaki K, Honda T, Kawai K, et al. Eradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. Eur J Clin Invest. 2005;35:214–9.CrossRefPubMed
37.
Farkas H, Fust G, Fekete B, Karadi I, Varga L. Eradication of Helicobacter pylori and improvement of hereditary angioneurotic oedema. Lancet. 2001;358:1695–6.CrossRefPubMed
38.
Nagashima R, Maeda K, Yuda F, Kudo K, Saitoh M, Takahashi T. Helicobacter pylori antigen in the glomeruli of patients with membranous nephropathy. Virchows Arch. 1997;431:235–9.CrossRefPubMed
39.
Eck M, Schmausser B, Scheller K, Toksoy A, Kraus M, Menzel T, et al. CXC chemokines Gro(alpha)/IL-8 and IP-10/MIG in Helicobacter pylori gastritis. Clin Exp Immunol. 2000;122:192–9.CrossRefPubMed
40.
Yokota K, Hirai Y, Haque M, Hayashi S, Isogai H, Sugiyama T, et al. Heat shock protein produced by Helicobacter pylori. Microbiol Immunol. 1994;38:403–5.PubMed
41.
Kobayashi K, Yokota K, Yoshino T, Kawahara Y, Dey A, Hirai Y, et al. Detection of Helicobacter pylori associated antigen and heat shock protein 60 on follicular dendritic cells in the germinal centres of low grade B cell lymphoma of gastric mucosa associated lymphoid tissue (MALT). J Clin Pathol. 1998;51:396–8.CrossRefPubMed
42.
Ishii E, Yokota K, Sugiyama T, Fujinaga Y, Ayada K, Hokari I, et al. Immunoglobulin G1 antibody response to Helicobacter pylori heat shock protein 60 is closely associated with low-grade gastric mucosa-associated lymphoid tissue lymphoma. Clin Diagn Lab Immunol. 2001;8:1056–9.PubMed
43.
Okada T, Ayada K, Usui S, Yokota K, Cui J, Kawahara Y, et al. Antibodies against heat shock protein 60 derived from Helicobacter pylori: diagnostic implications in cardiovascular disease. J Autoimmun. 2007;29:106–15.CrossRefPubMed
44.
Foteinos G, Afzal AR, Mandal K, Jahangiri M, Xu Q. Anti-heat shock protein 60 autoantibodies induce atherosclerosis in apolipoprotein E-deficient mice via endothelial damage. Circulation. 2005;112:1206–13.CrossRefPubMed
45.
Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, Dixon MF. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology. 1997;112:1386–97.CrossRefPubMed
46.
Dey A, Yokota K, Kobayashi K, Oguma K, Hirai Y, Akagi T. Antibody and cytokine responses in Helicobacter pylori-infected various mouse strains. Acta Medica Okayama. 1998;52:41–8.PubMed
47.
Yamaguchi H, Osaki T, Kai M, Taguchi H, Kamiya S. Immune response against a cross-reactive epitope on the heat shock protein 60 homologue of Helicobacter pylori. Infect Immun. 2000;68:3448–54.CrossRefPubMed
48.
Kiechl S, Willeit J. The natural course of atherosclerosis. Part II: vascular remodeling. Bruneck Study Group. Arterioscler Thromb Vasc Biol. 1999;19:1491–8.PubMed
49.
George J, Afek A, Gilburd B, Shoenfeld Y, Harats D. Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice. J Am Coll Cardiol. 2001;38:900–5.CrossRefPubMed
50.
Wolin SL, Reinisch KM. The Ro 60 kDa autoantigen comes into focus: interpreting epitope mapping experiments on the basis of structure. Autoimmun Rev. 2006;5:367–72.CrossRefPubMed
51.
Veillard NR, Steffens S, Pelli G, Lu B, Kwak BR, Gerard C, et al. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation. 2005;112:870–8.CrossRefPubMed
52.
Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci USA. 2005;102:1596–601.CrossRefPubMed
Metadata
Title
Autoimmunity, Infectious Immunity, and Atherosclerosis
Authors
Eiji Matsuura
Kazuko Kobayashi
Yukana Matsunami
Lianhua Shen
Nanhu Quan
Marina Makarova
Sergey V. Suchkov
Kiyoshi Ayada
Keiji Oguma
Luis R. Lopez
Publication date
01-11-2009
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 6/2009
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-009-9333-5

Other articles of this Issue 6/2009

Journal of Clinical Immunology 6/2009 Go to the issue

OriginalPaper

Myocarditis: Infection Versus Autoimmunity

OriginalPaper

Impairment of Monocyte-derived Dendritic Cells in Idiopathic Pulmonary Arterial Hypertension

ReviewPaper

Immunological Challenges of Cardiac Transplantation: The need for Better Animal Models to Answer Current Clinical Questions

OriginalPaper

IL-2, IFN-γ, and IL-12 Gene Polymorphisms and Susceptibility to Multiple Sclerosis

OriginalPaper

Dectin-1 is Inducible and Plays an Essential Role for Mycobacteria-Induced Innate Immune Responses in Airway Epithelial Cells

OriginalPaper

Tissue Transglutaminase Can Be Involved in Airway Inflammation of Toluene Diisocyanate-Induced Occupational Asthma
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits